Insilico Medicine and SK Biopharmaceuticals have entered into a significant research collaboration valued at over $2.5 billion. The partnership will leverage Insilico's AI-driven Pharma.AI platform to discover novel drug candidates for neuroimmune diseases, with SK Biopharmaceuticals leading the subsequent development and commercialization phases. This deal represents Insilico's largest partnership to date with an Asia-Pacific entity and highlights the growing trend of AI integration in pharmaceutical research, particularly with Korean companies showing increased adventurousness in the sector. AI
IMPACT Accelerates AI integration in drug discovery, potentially leading to faster development of novel therapies for complex diseases.
RANK_REASON Partnership between two companies involving AI for drug discovery with a significant monetary value.
- 36Kr
- Cowos
- Insilico Medicine
- SK Hynix
- Alex Zhavoronkov
- Eli Lilly
- Nvidia
- Samsung Electronics
- SK Group
AI-generated summary · Google Gemini · from 2 sources. How we write summaries →
